Congress Materials

Medical Information
Gulf Countries
 

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
SelectI am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
I am a patient / caregiverNo, go back to the patient portal
SelectI am a patient / caregiverNo, go back to the patient portal
I am a Healthcare Professional in another country.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Oral Presentation
Yamaguchi Y, Peeva E, Shore R, Han G, Cox LA, Banerjee A, Thaci D, Hamzavi I, Sloan A, Ganesan AK, Ezzedine K March 29, 2022 AAD 2022 Vitiligo

Ritlecitinib (PF-06651600), an oral JAK3/TEC inhibitor, stabilizes active lesions and promotes re-pigmentation of stable lesions in patients with active non-segmental vitiligo: results from a Phase 2b, randomized, placebo-controlled, dose-ranging study

View Presentation
Oral Presentation
King B, Szepietowski JC, Farrant P, Hordinsky M, Lejeune A, Zwillich SH, Wajsbrot D, Wolk R March 29, 2022 AAD 2022 Alopecia

Safety of the oral JAK3/TEC inhibitor ritlecitinib (PF-06651600) in patients with alopecia areata: results from the ALLEGRO Phase 2b/3, randomized, double-blind, placebo-controlled trial

View Presentation
Oral Presentation
Melinda J Gooderham, Mark G Lebwohl, Eric L Simpson, Andreas Wollenberg, Andrew G Bushmakin, Joseph C Cappelleri, Marco DiBonaventura, Ricardo Rojo, Melissa Watkins, Hernan Valdez, Daniela E Myers March 29, 2022 AAD 2022 Atopic Dermatitis

Time to Improvement in Daily Signs and Symptoms Associated With Atopic Dermatitis (AD) in Patients With Moderate-to-Severe AD in Pooled Monotherapy Studies of Abrocitinib

View Presentation